Trade Valneva SE - VLA CFD

Valneva SE Company profile

About Valneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Financial summary

BRIEF: For the six months ended 30 June 2021, Valneva SE revenues decreased 1% to EUR47.5M. Net loss applicable to common stockholders increased from EUR25.6M to EUR86.4M. Revenues reflect Commercialized Vaccines segment decrease of 22% to EUR31.8M, Canada segment decrease of 75% to EUR2M, United Kingdom segment decrease of 75% to EUR1.1M, Europe excluding France segment decrease of 42% to EUR4.2M.

Equity composition

07/2010, Rights Issue, 2 new shares for every 5 shares held @ EUR 5.06 (Factor: 1.12817). 6/2013, Rights Issue, 5 new shares for every 13 shares held @ EUR2.65 (Factor: 1.11881). 1/2015, Rights Issue, 11 new shares for every 34 shares held @ EUR2.47 (Factor: 1.10896).